2,4,5-Trimethylfuran-3-carbaldehyde | 1521449-77-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,4,5-Trimethylfuran-3-carbaldehyde
• CAS: 1521449-77-3
• 化学式: C₈H₁₀O₂
• 分子量: 138.16
• InChiKey: VQJWBUBKCGSNMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 17BetaHSD Type 5 Inhibitor
  申请人：Niimi Tatsuya

  公开号：US20110071146A1

  公开（公告）日：2011-03-24

  To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

  提供一种新颖和优秀的方法，用于基于对17βHSD类型5的选择性抑制活性，治疗和/或预防前列腺癌、良性前列腺增生、痤疮、脂溢性皮炎、多毛症、秃发、脱发、早熟、肾上腺增生、多囊卵巢综合症、乳腺癌、肺癌、子宫内膜异位症、平滑肌瘤等疾病。发现一种N-磺酰基吲哚衍生物，其中吲哚环在其碳原子上被羧基取代，或者被羧基取代的低烷基或低烯基取代，具有强大的选择性抑制17βHSD类型5的活性，可能成为治疗和/或预防良性前列腺增生、前列腺癌等疾病的治疗剂和/或预防剂，而不伴随着由于睾酮降低而产生的不良药物反应，因此本发明得以完成。
• Furyl-nonatetraene derivatives and the pharmaceutically acceptable salts thereof, processes for their preparation, starting compounds used in these processes, and pharmaceutical compositions containing them
  申请人：F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft

  公开号：EP0008665A1

  公开（公告）日：1980-03-19

  The new furyl-nonatetraene derivatives of the formula and the pharmaceutically acceptable salts thereof, e.g. (E, E, E, E,) -3,7-dimethyl-9-(2,4,5-trimethyl-3-furyl)- 2,4,6,8- nonatetraenoic acid ethyl ester, are effective in regressing the growth of tumors and chondrosarcoma and they are useful as medicaments for therapy of acne, psoriasis and other dermatological disorders. They may be therefore included in pharmaceutical preparations. The compounds of the formula may be prepared by a process which comprises a) reacting a compound of the formula with a new compound of the formula or b) reacting a new compound of the formula with a compound of the formula or The meaning of the substituents see inside the description.

  式中的新呋喃基-壬四烯衍生物及其药物可接受盐，例如 及其药学上可接受的盐类，例如（E，E，E，E，E，）-3,7-二甲基-9-（2,4,5-三甲基-3-呋喃基）-2,4,6,8-壬四烯酸乙酯，可有效抑制肿瘤和软骨肉瘤的生长，并可用作治疗痤疮、牛皮癣和其他皮肤病的药物。因此，它们可用于药物制剂中。 式中化合物的制备过程包括 a) 将式化合物 与一种新的式化合物反应 或 b) 将一种新的式化合物 与式化合物反应 或 取代基的含义见说明。
• 17 BETA HSD TYPE 5 INHIBITOR
  申请人：Astellas Pharma Inc.

  公开号：EP1990335A1

  公开（公告）日：2008-11-12

  To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone; and the present invention has thus been completed.

  提供一种基于对 17βHSD 5 型的选择性抑制活性的治疗和/或预防前列腺癌、良性前列腺增生、痤疮、脂溢性皮炎、多毛症、秃头、脱发、性早熟、肾上腺肥大、多囊卵巢综合征、乳腺癌、肺癌、子宫内膜异位症、子宫肌瘤等疾病的新型优良方法。 研究发现，一种 N-磺酰基吲哚衍生物，其吲哚环的碳原子上被羧基、羧基取代的低级烷基或羧基取代的低级烯基取代，对 17βHSD 5 型具有强效的选择性抑制活性，可成为良性前列腺增生、前列腺癌等的治疗剂和/或预防剂，且不会因睾酮减少而伴随药物不良反应；本发明由此完成。